Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$30.81
+3.0%
$31.00
$24.10
$62.53
$2.89B0.31855,011 shs753,519 shs
Merus stock logo
MRUS
Merus
$55.41
+10.8%
$42.99
$33.19
$61.28
$3.83B0.94735,183 shs1.54 million shs
Opthea Limited stock logo
OPT
Opthea
$3.41
$3.41
$1.79
$6.30
$524.84M1.1226,802 shsN/A
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
$29.93
+3.7%
$30.55
$6.76
$46.98
$2.84B0.371.27 million shs271,496 shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
+1.39%-0.13%-9.66%-9.94%-36.17%
Merus stock logo
MRUS
Merus
-1.56%+15.74%+10.45%+8.20%-8.86%
Opthea Limited stock logo
OPT
Opthea
0.00%0.00%0.00%-25.87%+8.77%
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
-5.28%-6.05%-8.87%-19.74%+179.38%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
3.7577 of 5 stars
3.51.00.03.73.62.50.0
Merus stock logo
MRUS
Merus
2.8438 of 5 stars
4.62.00.00.02.61.70.0
Opthea Limited stock logo
OPT
Opthea
0.9276 of 5 stars
2.10.00.00.02.70.80.6
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
4.3771 of 5 stars
3.52.00.04.43.53.30.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
2.91
Moderate Buy$74.56141.98% Upside
Merus stock logo
MRUS
Merus
3.13
Buy$86.0055.20% Upside
Opthea Limited stock logo
OPT
Opthea
2.17
Hold$1.33-60.90% Downside
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
3.00
Buy$42.6742.55% Upside

Current Analyst Ratings Breakdown

Latest OPT, CRNX, MRUS, and SRRK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/23/2025
Merus stock logo
MRUS
Merus
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
5/19/2025
Merus stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$75.00 ➝ $75.00
5/14/2025
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$50.00
5/8/2025
Merus stock logo
MRUS
Merus
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$91.00 ➝ $89.00
4/28/2025
Merus stock logo
MRUS
Merus
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/9/2025
Merus stock logo
MRUS
Merus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$83.00 ➝ $83.00
3/28/2025
Merus stock logo
MRUS
Merus
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$109.00 ➝ $109.00
3/25/2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
3/25/2025
Opthea Limited stock logo
OPT
Opthea
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral$12.00 ➝ $2.00
3/25/2025
Opthea Limited stock logo
OPT
Opthea
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$12.00 ➝ $1.00
3/25/2025
Opthea Limited stock logo
OPT
Opthea
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Underperform$8.00 ➝ $1.00
(Data available from 5/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
$760K3,795.79N/AN/A$8.07 per share3.82
Merus stock logo
MRUS
Merus
$54.73M70.08N/AN/A$6.17 per share8.98
Opthea Limited stock logo
OPT
Opthea
$87.67K5,986.77N/AN/A($0.56) per share-6.09
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
$33.19M85.62N/AN/A$3.12 per share9.59
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$214.53M-$3.82N/AN/AN/AN/A-36.12%-31.89%8/6/2025 (Estimated)
Merus stock logo
MRUS
Merus
-$154.94M-$4.08N/AN/AN/A-680.61%-38.89%-31.16%7/30/2025 (Estimated)
Opthea Limited stock logo
OPT
Opthea
-$220.24MN/A0.00N/AN/AN/AN/AN/AN/A
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
-$165.79M-$2.53N/AN/AN/AN/A-145.60%-91.83%8/14/2025 (Estimated)

Latest OPT, CRNX, MRUS, and SRRK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
Merus stock logo
MRUS
Merus
-$1.17-$1.40-$0.23-$1.40$7.82 million$26.49 million
5/14/2025Q1 2025
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
-$0.63-$0.67-$0.04-$0.67N/AN/A
5/8/2025Q1 2025
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
-$0.99-$1.04-$0.05-$1.04$0.10 million$0.36 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/AN/AN/AN/AN/A
Merus stock logo
MRUS
Merus
N/AN/AN/AN/AN/A
Opthea Limited stock logo
OPT
Opthea
N/AN/AN/AN/AN/A
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
N/A
16.39
16.38
Merus stock logo
MRUS
Merus
N/A
8.32
8.32
Opthea Limited stock logo
OPT
Opthea
N/A
2.94
2.94
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
0.63
3.88
3.88

Institutional Ownership

CompanyInstitutional Ownership
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
98.51%
Merus stock logo
MRUS
Merus
96.14%
Opthea Limited stock logo
OPT
Opthea
55.95%
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
91.08%

Insider Ownership

CompanyInsider Ownership
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
4.60%
Merus stock logo
MRUS
Merus
4.57%
Opthea Limited stock logo
OPT
Opthea
3.20%
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
13.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Crinetics Pharmaceuticals, Inc. stock logo
CRNX
Crinetics Pharmaceuticals
21093.63 million87.17 millionOptionable
Merus stock logo
MRUS
Merus
3769.21 million65.34 millionOptionable
Opthea Limited stock logo
OPT
Opthea
8153.91 million148.98 millionNot Optionable
Scholar Rock Holding Co. stock logo
SRRK
Scholar Rock
14094.95 million75.64 millionOptionable

Recent News About These Companies

Wedbush Forecasts Scholar Rock's Q2 Earnings (NASDAQ:SRRK)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Crinetics Pharmaceuticals stock logo

Crinetics Pharmaceuticals NASDAQ:CRNX

$30.81 +0.90 (+3.01%)
As of 01:14 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Merus stock logo

Merus NASDAQ:MRUS

$55.41 +5.40 (+10.81%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Opthea stock logo

Opthea NASDAQ:OPT

$3.41 0.00 (0.00%)
As of 05/28/2025

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

Scholar Rock stock logo

Scholar Rock NASDAQ:SRRK

$29.93 +1.07 (+3.71%)
As of 01:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.